Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels(Cliniques Universitaires Saint-Luc), Paul M. Clément(Universitair Ziekenhuis Leuven), Annika Flygare(Genmab (Denmark)), Gábor Répássy(Semmelweis University), Ágnes Ruzsa(Baranya Megyei Kórház), Igor Lifirenko(Kursk Regional Clinical Oncology Center), Per Soelberg Sørensen(University of Copenhagen), Somasundaram Subramanian(Russian Cancer Research Center NN Blokhin), Tina Nielsen(Roche (Switzerland)), Steen Lisby(Genmab (Denmark))
Cited by 242
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Multiple Sclerosis Severity Score
|Neurology|2005|959